What is the recommended treatment approach for a patient presenting with purpura?

Treatment of Purpura

The treatment of purpura depends entirely on the underlying cause: for immune thrombocytopenic purpura (ITP), first-line treatment includes corticosteroids (prednisone 1-4 mg/kg/day), intravenous immunoglobulin (IVIg 0.8-1 g/kg), or IV anti-D immunoglobulin in Rh(D)-positive patients; for life-threatening purpura fulminans, immediate administration of third-generation cephalosporins, fresh frozen plasma, and urgent referral to intensive care is mandatory; for thrombotic thrombocytopenic purpura (TTP), immediate plasma exchange with corticosteroids and caplacizumab is essential.

Algorithmic Approach by Purpura Type

Immune Thrombocytopenic Purpura (ITP)

When to Treat:

• Treat all patients with severe bleeding symptoms 1
• Consider treatment for moderate bleeding or increased bleeding risk 1
• Many patients with platelet counts 20-30 × 10⁹/L without symptoms can be observed ("watch and wait") 1
• Approximately two-thirds of children improve spontaneously within days to 6 months 1

First-Line Treatment Options 1:

1. Corticosteroids (Predniso(lo)ne)

   • Standard dose: 1-2 mg/kg/day
   • High-dose short course: 4 mg/kg/day for 3-4 days achieves platelet count ≥50 × 10⁹/L in 72-88% of children within 72 hours
   • Use only to maintain hemostatic platelet count and for shortest duration possible due to serious side effects in children
   • Expected response: 2-7 days
   • Side effects: transient mood changes, gastritis, weight gain; caution with active infection (especially varicella) or GI bleeding

2. Intravenous Immunoglobulin (IVIg)

   • Dose: 0.8-1 g/kg as single dose (supersedes older 0.4 g/kg daily for 2-5 days regimen)
   • Raises platelet count in >80% of children, more rapidly than corticosteroids
   • Repeat dosing based on short-term platelet response
   • Side effects: fever, headache, nausea/vomiting (highest with 1 g/kg on consecutive days)

3. IV Anti-D Immunoglobulin

   • Only for Rh(D)-positive patients
   • Given as short infusion, transiently raises platelet counts
   • Critical caveat: Mild extravascular hemolysis is common; rare cases of intravascular hemolysis, disseminated intravascular coagulation, and renal failure reported in pediatric patients with comorbidities

Emergency/Life-Threatening Bleeding:

• Administer 2-3 fold larger-than-usual dose of platelets
• Plus IV high-dose corticosteroids
• Plus IVIg or IV anti-D 1
• Goal: elevate platelet count to reduce bleeding risk

Purpura Fulminans

This is a dermatological and hematological emergency with 20-25% mortality 2, 3. Characterized by extensive skin necrosis and disseminated intravascular coagulation 4, 5.

Immediate Recognition Criteria 2, 3:

• Febrile purpura with vasculitic rash (use "tumbler test" - rash does not disappear with pressure)
• Even ONE ecchymosis >3 mm diameter with signs of infection should raise suspicion
• Painful, well-demarcated purpuric lesions evolving to necrotic eschars 5

Immediate Pre-Hospital Management 2, 3:

• Administer third-generation cephalosporin IMMEDIATELY before biological investigations or hospital transfer
• This preadmission antibiotic has protective effect on mortality (odds ratio: 0.36; 95% CI: 0.23-0.56)

Hospital/ICU Management 6, 2, 3, 5:

1. Initial stabilization:

   • Broad-spectrum antibiotics (continue third-generation cephalosporin)
   • Fresh frozen plasma (FFP) - controls acute disseminated intravascular coagulation and permits safe evaluation of other therapies 6
   • Corticosteroids
   • Fluid resuscitation and catecholamines for shock
   • Monitor for hypoglycemia (especially infants) and hypocalcemia 2, 3

2. Sequential therapeutic trial if FFP effective 6:

   • Venous antithrombotic agents (heparin trial)
   • Antiplatelet agents
   • Antifibrinolytic agents
   • Antiproteolytic agents

3. Coagulation support 5:

   • Protein C replacement (especially neonatal cases)
   • Therapeutic plasma exchange
   • Note: Antithrombin, protein C, tissue plasminogen activator, and vasodilator infusion have no proven efficacy 2, 3

4. Surgical management 4, 5:

   • Early surgical evaluation and intervention
   • Proper wound management
   • Skin grafts and/or amputations may be necessary (5-20% of survivors) 3
   • Early referral to burn center with multidisciplinary team recommended for best outcomes 4

Thrombotic Thrombocytopenic Purpura (TTP)

TTP is life-threatening with mortality of 12-16% without proper treatment 7, 8.

Diagnostic Gold Standard:

• ADAMTS13 activity measurement 7
• Early diagnosis is essential

Immediate Treatment Upon Clinical Suspicion 7:

1. Plasma exchange - reduces mortality from 15.7% to 3.9% 7
2. Corticosteroids
3. Caplacizumab (anti-VWF therapy) - halts thrombotic microangiopathy earlier, prevents early relapses, potentially lowers mortality 7, 8

Emerging Standard of Care 8:

• Anti-VWF therapy (caplacizumab)
• Glucocorticoids
• Early immunosuppression with anti-CD20 agents (rituximab)
• Standard treatment with plasma exchange, corticosteroids, caplacizumab, and rituximab associated with 2.2% mortality versus 12.2% in historical controls 7
• TPE may be foregone in selected cases based on ADAMTS13 activity levels and clinical response 8

Follow-up Management 7:

• Regular clinical follow-up
• ADAMTS13 monitoring
• Detection and treatment of late sequelae
• For pregnancy: monitoring and recurrence prophylaxis recommended

Critical Pitfalls to Avoid

1. Do not delay antibiotics in suspected purpura fulminans - administer third-generation cephalosporin before any investigations or transfer 2, 3
2. Recognize shock is difficult in children - do not wait for obvious hypotension 2, 3
3. Avoid prolonged corticosteroid use in ITP children due to serious side effects 1
4. Use IV anti-D only in Rh(D)-positive patients and monitor for hemolysis 1
5. Do not use unproven therapies in purpura fulminans (antithrombin, protein C infusions, tissue plasminogen activator) as they lack efficacy evidence 2, 3
6. Initiate TTP treatment immediately on clinical suspicion - do not wait for ADAMTS13 results 7